Interleukin-6 Blockade Abrogates Immunotherapy Toxicity and Promotes Tumor Immunity

Researchers performed a deep immune analysis of intestinal, colitis, and tumor tissue from immune checkpoint blockade-treated patients with parallel studies in preclinical models.